Inactive Instrument

Provention Bio, Inc. Stock price

Equities

PRVB

US74374N1028

Pharmaceuticals

Dynamic Chart
Managers TitleAgeSince
Founder 52 16-10-03
Director of Finance/CFO - 23-04-26
President - 23-04-26
Members of the board TitleAgeSince
Founder 52 16-10-03
President - 23-04-26
Treasurer - -
More insiders
Provention Bio, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing the development and commercialization of investigational therapies that intercept and prevent debilitating and life-threatening immune-mediated diseases. The Company's pipeline includes TZIELD (teplizumab-mzwv), PRV-3279, Ordesekimab and PRV-101. TZIELD (teplizumab-mzwv) is a CD3-directed antibody indicated to delay the onset of stage three T1D in adults and pediatric patients aged eight years and older with stage two T1D. It is also developing TZIELD for use in stage three newly diagnosed T1D patients. PRV-3279 is a humanized bispecific scaffold molecule targeting the B-cell surface proteins for the treatment of SLE and for the prevention of immunogenicity of biotherapeutics. Ordesekimab is a human anti-interleukin 15 (IL-15) monoclonal antibody for the treatment of gluten-free diet non-responsive celiac disease. PRV-101 is a CVB vaccine to prevent acute CVB infections.
More about the company
  1. Stock
  2. Equities
  3. Stock Provention Bio, Inc. - Nasdaq